A Few End of Year Thoughts
It seems like I was writing to you yesterday during the heat of the summer, and now winter is here! For many of us, snow has already fallen, reminding us that the year is coming to a close.
As you work on closing out 2019 and meeting your business goals, I wanted to share a few final resources with you that hopefully help to inform your planning for 2020 and remind you that we are here to partner with you. Our staff continues to publish impressive pieces, from research on modeling to commentaries in the Wall Street Journal, and our team continues to be on the cutting edge. We are here to support your work, whether it be responding to ICER, running a microsimulation, or quantifying the value of gene and cell therapies.
This end of year newsletter is packed with resources for you as you go into 2020. We’ve hosted 2 webinars this quarter, one on top trending topics in HEOR/market access and one on the value of gene and cell therapies. We’ve also provided you with the latest Precision white paper on the challenges of gene and cell therapy approval and commercialization.
As always, don’t hesitate to reach out if you’d like to talk to me or any of our HEOR team members about your priorities for 2020. I hope you all have a wonderful holiday and Happy New Year!
| Ross Maclean, MD, PhD, MBA Executive Vice President and General Manager Ross.Maclean@PrecisionXtract.com Want updates? Follow Precision Xtract on LinkedIn! |
 |
Download the New White Paper: What Do Value Assessments Miss?
From Precision scientific advisor and Harvard professor Dr. Anupam Bapu Jena, this new White Paper presents a fresh approach on developing value assessment strategies, exploring how the definition of value can extend beyond quality, and cost of care.
Our Latest Webinar Now On Demand! Demonstrating the Short- and Long-term Value of Gene and Cellular Therapies
Larry Blandford, EVP, Managing Partner for Precision, moderates a video panel discussion tackling the evergreen challenge of how to demonstrate the short- and long-term value of a therapy when clinical data are lacking. The panel includes a variety of stakeholder perspectives, from payers to IDNs to economists. With Precision’s Jeremy Schafer, Avi Mamidi, Rebecca Dean, and David Carr.
Download the New White Paper: Delivering on the Promise of Cell Therapy: Challenges and Trends
Get the new White Paper, Delivering on the Promise of Cell Therapy: Challenges and Trends, from Precision to explore the current landscape of cell therapy, with an emphasis on CAR-T products, highlighting the key challenges and opportunities sponsors face as they endeavor to translate these innovative treatments from the bench to the bedside.
HEOR in 2020: 4 Trends in Market Access Did You Miss Our Live Webinar Panel?
In this unique 1-hour video webinar cosponsored by HealthEconomics.com, Dr. Patti Peeples, HealthEconomics.com Founder and CEO, moderates a live panel discussion with Precision’s Dr. Peter Neumann, Dr. Anuam Jena, Dr. Jeroen Jansen, and Dr. Kathy Lang, discussing some of the year’s key trends and topics in HEOR, and what you need to know to be successful in 2020.
Precision’s Shafrin in the Wall Street Journal: Drug Pricing and the Broader Quality of Life
Great recent thought leadership in the Wall Street Journal from Senior Director Jason Shafrin. In WSJ’s Opinion, he asks the question: Does ICER's pricing model threaten innovative health therapies?
Want updates? Follow PRECISIONheor on LinkedIn!